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Summary  
Background: Tinea pedis and onychomycosis are among the commonest fungal diseases in the 
world. Dermatophytes and, less frequently, non-dermatophyte molds are etiological agents of 
foot mycosis and could be able to form biofilms. Fungal biofilm has demonstrated increasing 
drug resistance Objectives: This work aims to evaluate in vitro the ability to form biofilm and 
the susceptibility to antifungal drugs of sessile dermatophytes and non-dermatophyte molds 
involved in foot mycosis. Methods: Thirty-six dermatophytes and non-dermatophyte molds 
isolated from Tunisian patients with foot mycoses, and identified with MALDI-TOF have been 
tested. MICs of fluconazole, econazole, itraconazole, terbinafine and griseofulvin were carried 
out using CLSI broth microdilution method. The ability to form biofilm and antifungal activities 
of drugs against fungal biofilm formation has been quantified by Crystal Violet and Safranin Red 
staining. Results: Biomass quantification revealed that all species studied were able to form 
biofilms in vitro after 72h. Fluconazole, econazole, itraconazole and terbinafine inhibited fungal 
growth with MIC values ranging from 0.031 to >64 µg ml
-1
. The best antifungal activity has been 
obtained with terbinafine against Fusarium solani. Econazole showed the highest activity against 
fungal biofilm formation. Conclusion: These findings can help clinicians to develop the 
appropriate therapy of foot mycosis. 
 
Introduction  
Tinea pedis and onychomycosis are among the commonest fungal diseases in the world; these 
affect the elderly, children and adults 
1-3
. The most frequently identified fungi are dermatophytes. 
Trichophyton rubrum is the most common specie but various non-dermatophyte molds (NDMs) 
are also isolated from diseased nails such as Scopulariopsis brevicaulis, Fusarium spp., 
Aspergillus spp. 
4-6
. Among the known Aspergillus spp., A. versicolor and A. sydowii are the 
species most commonly associated to foot infections, including onychomycosis, other species 
like A. candidus, A. fumigatus, A. niger, A. flavus, A. terreus, A. ochraceus and A. sclerotiorum 
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are also incriminated 
7,8
. Fusarium solani and Fusarium oxysporum are etiological agents of 
onychomycosis caused by Fusarium species 
9
. 
These infections are considered as an important public health problem, constituting a large bulk 
of cases attending the dermatology departments and this can be due to the high prevalence, long-
term therapy and difficult eradication of recurrent chronic nails infection
10-12
.  
The treatment of foot mycosis can be local but essential systemic treatment is required depending 
to the type and location of lesions. Currently the treatment of dermatophyte infections is usually 
long term, with several cases of recurrence 
13
.  
Furthermore, systemic antifungal agents present many disadvantages such as therapeutic 
limitations with high toxicity, many drugs interactions and resistance 
14
. In another hand, the 
study of antifungal susceptibility mechanism constitutes an important strategy to restrict the 
emergence of resistance to the commercially available agents and may help to provide the 
efficacy of an antifungal drug, so that the development of new and potential compounds is 
necessary 
15
. 
Dermatophytes and NDMs have the ability to adhere on biotic or abiotic surface forming biofilms 
16-18
. Fungal biofilm represent an important role in the pathogenesis and in the resistance to the 
antimicrobial agents
18
. Many methods have been developed to evaluate the quantity of biofilm 
19,20
. The Cristal violet assay has been demonstrated to be the most reliable test, which stains 
metabolically active and inactive cells in mature biofilms 
21
.  
The aims of the present study were to evaluate the in vitro ability to form biofilms and antifungal 
susceptibility of clinical isolates of dermatophytes and NDMs implicated in foot mycosis. Crystal 
Violet and Safranin Red staining quantified the amount of biofilm. 
 
Materials and methods 
Fungal strains 
Clinical strains were isolated from patients with foot mycosis attending the Mycology Unit of the 
dermatology Department in the University Hospital la Rabta (Tunis) until a prospective study 
enrolled in Tunisia 
22
. Thirty six strains were included in this study (Table 1), 26 dermatophyte 
species including Trichophyton rubrum (n=21), Trichophyton interdigitale (n=5), and 10 molds 
including Scopulariopsis brevicaulis (n=3), Fusarium solani (n=2), Fusarium oxysporum (n=2), 
Chrysosporium keratinophylum (n=2) and Aspergillus terreus (n=1). T. mentagrophytes DSM 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
4870 and A. terreus DSM 1958 from German Collection of Microorganisms (DSMZ, 
Braunschweig, Germany), were used as references strains. Initially, all isolates were identified 
using standard methods based on macroscopic and microscopic characteristics. Then, 
identification of fungal strains was confirmed by analysis of protein using MALDI-TOF MS 
(Parasitology-Mycology Unit in the Department of Microbiology, Necker-Enfants Malades 
Hospital AP-HP, Paris, France). Isolates were stored at – 80°C on Sabouraud Broth (Sigma 
Aldrich, St. Louis Missouri, USA) with 30% glycerol until the time of use.  
 
Antifungal susceptibility assay 
The minimal inhibitory concentration (MIC) on planktonic cells was determined using the broth 
microdilution method according to the Clinical and Laboratory Standards Institute reference for 
filamentous fungi 
23
. All strains were grown on Potato Dextrose Agar (Sigma Aldrich, St. Louis 
Missouri, USA) at 28-30°C until conidia formation. Inoculum suspension was prepared at final 
concentration of 0.4×10
4
 to 5×10
4
 CFU ml
-1
. The in vitro antifungal activity was evaluated using 
five antifungal agents: fluconazole (FLC), econazole (ECO) (Sigma Aldrich, St. Louis Missouri, 
USA), with concentrations ranged from 64 to 0.125 µg ml
-1
 respectively and for itraconazole 
(ITC), terbinafine (TRB) and griseofulvin (GSF) (Sigma Aldrich, St. Louis Missouri, USA) from 
16 to 0.032 µg ml
-1
. MIC50 was defined as the lowest concentration that caused ≥ 50% growth 
inhibition; MIC80 was the lowest concentration that caused 80% growth inhibition and the MIC100 
the lowest drug concentration that inhibited 100% of growth.  
 
Evaluation of biofilm formation 
The biofilm assay was performed with the use of methods described previously
19,24
. All strains 
were grown on Potato dextrose agar (Sigma Aldrich, St. Louis Missouri, USA), incubated at 
28°C until sporulation. The inoculum was standardized to 1×10
6 
conidia ml
-1
 in RPMI 1640 
medium supplemented with L-glutamine, buffered with MOPS acid (Sigma–Aldrich), and added 
to 24-well plates. After 24-72h at 37°C, the cells were washed two times with sterile saline water 
0.9% for removal of non-adherent cells. Morphology of biofilm was observed by light 
microscopy. 
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Biofilm quantification 
Crystal Violet 
19,24
 and Safranin Red 
25
 bind to negatively charged molecules and can be used to 
stain and quantify total biomass comprising fungi and EPS Total Biomass 
Cristal violet staining 
After biofilm formation, the plates are dried at room temperature for 10 min and 1ml of 0.5% 
Crystal Violet solution was added to each well for 30 min. The wells were washed two times with 
sterile water to remove excess of crystal violet and biofilm were decolorized by the addition of 
1ml of 80:20 ethanol/acetone solutions to each well. This solution was gently homogenized with 
a pipette until the rest of the crystal violet was completely dissolved (~ 1 min). Finally, the 
solution from each well was transferred to a new 96-well plate and then read in a microplate 
reader at 570 nm. All experiments were performed in triplicate. 
Safranin staining   
After the biofilm formation for 72h in 96-well plates, the plates were washed three times with 
200µl of phosphate buffered saline (PBS) (Sigma Aldrich, St. Louis Missouri, USA) and dried at 
50°C for 30 min. Each well was stained with 50 µl of safranin solution 1% for 5 min, and then 
washed three times with 200 µl of PBS until the supernatant stayed clear. Finally, the optical 
density OD was read at 492 nm. 
 
Antifungal susceptibility of dermatophyte and NDM biofilms  
All strains were grown on Potato dextrose agar (Sigma Aldrich, St. Louis Missouri, USA), 
incubated at 28°C until sporulation. The inoculum was standardized to 1×10
6
conidia ml
-1
 in 
RPMI 1640 medium supplemented with L-glutamine and buffered with MOPS acid (Sigma–
Aldrich) and was allowed to form biofilm in 96-well polystyrene plates in the presence of five 
concentrations of ECZ and TER (16, 8, 4, 2 and 1 µg ml
-1
). After incubation, the biofilm was 
quantified using crystal violet staining as previously described 
20,23
. The concentrations causing 
50% inhibition of biofilm formation due to drug treatment have been determinated. 
 
Statistical analysis 
The antifungal activities are the result of three independent experiments performed in duplicate. 
The data of antifungal activity (MIC) have been presented as median. In order to relate the 
biofilm content and, the MIC values of the different strains Pearson’s correlation coefficient (r) 
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have been estimated. The correlation coefficient close to 1 indicates that the variables are 
positively and linearly related. The zero value indicates weak relationship between the variables, 
a correlation less than 0.5 is weak. 
 
Results 
The results of antifungal activity (MIC50, MIC80, and MIC100) of FLC, ECO, ITC, TRB and GSF 
against planktonic cells of dermatophytes (T. rubrum, T. interdigitale) and NDMs (F. solani, F. 
oxysporum, A. terreus, S. brevicaulis and C. keratinophylum have been reported in Table 2. 
Fusarium spp., S. brevicaulis and A. terreus were resistant to FLC (MIC50 >64 µg ml
-1
), ITC 
(MIC50 >16 µg ml
-1
) and GSF (MIC80 >16 µg ml
-1
). The strains of F. solani were resistant to all 
antifungal tested (MIC100>16 µg ml
-1
for ITC, TER, GSF and MIC50>64 µg ml
-1
for FLC, ECO). 
All the Trichophyton spp. strains were susceptible to TRB with MIC80 values of < 0.032 µg ml
-1
.  
Trichophyton spp, causing tinea pedis showed resistance to FLC with MIC80 values of  ≥ 64µg  
ml
-1
. 
All the strains demonstrated the ability to form biofilm on 24-well microtitration plate surface, 
however differences were observed among them (Fig. 1). T. rubrum (T21; T40 and T25) 
biofilms, T.interdigitale (T1) biofilm, F. oxysporum (M1 and M2) biofilms, S. brevicaulis (M3; 
M6 and M12) biofilms, C. keratinophylum (T37) biofilm and A. terreus (M5) biofilm produce a 
high amount of biomass (Fig. 1). In the present study, the species of F. solani (M7, M8) and S. 
brevicaulis (M3, M6) resistant clinical isolates, showed the most capacity to form biofilm on a 
polystyrene surface. 
The results of biomass quantification of all isolates were presented in Figure 1, showed a 
correlation between Crystal violet (Fig. 1a) and Safranin staining amount (r = 0.694)(Fig 1b). 
The amount of mature biofilm was not correlated to antifungal activity against all planktonic cells 
tested FLC-MIC80 values (r = 0.4422), FLC-MIC100 (r= 0.0584), ECO-MIC80 values (r=0.2135), 
ITC-MIC80 values (r=0.3534) and TRB-MIC80 values (r=0.1317). 
The antifungal activity of ECO and TRB against biofilm formation was measured in terms of 
percentage of inhibition and the results are shown in Figure 2. The effect of antifungal agents 
against biofilm formation was measured in terms of the percentage of inhibition; the in vitro 
assay showed that at concentration of 4µg ml
-1
, the percentage ranged from 0% to 95% for ECO 
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and from 4% to 93% for TRB. The best results were obtained with the ECO when compared with 
TRB on the strains tested. 
However, for Fusarium species (M2 and M8), the in vitro biofilms assay showed a low 
susceptibility to the tested antifungal agents.  
 
Discussion  
The commonest agents of foot mycosis are dermatophytes such as the anthropophilic T. rubrum 
26,27
 also NDMSs like Fusarium spp., S. brevicaulis and Aspergillus sp. can be incriminated but 
in low rates 
22,28-30
. The first step of treatment of tinea pedis and tinea unguium is to make precise 
diagnosis in order to provide the appropriate antifungal agent.  Recently, the therapy of foot 
mycosis represents a major challenge, frequent failures and recurrent infection are observed 
31-33
, 
inappropriate selection of antifungal agents in addition to inadequate dose and duration of therapy 
could facilitates the rapid recurrence of infection and also the development of drug resistance. 
The methods of the in vitro antifungal activity can be useful to predict the capacity of a 
determined antifungal agent to detect the resistance trends and to eradicate the determined fungal 
species. To our knowledge, few studies have been conducted in Tunisia focused on the antifungal 
susceptibility among dermatophytes and NDMs responsible for foot mycosis. Actually, ITC, FLC 
and TRB are the most widely available antifungal agents used for systemic treatment of 
onychomycosis. In order to have successful therapy for biofilm onychomycosis, it is necessary to 
use an antifungal especially for biofilm degradation. Although, many systemic antifungal drugs 
had also been associated with some adverse side effects such as headache, hepatotoxicity, 
gastrointestinal disturbance (nausea, diarrhea, vomiting), skin rash and impotency 
34,35
 and for 
this reason it is important that therapy be preceded by drug sensitivity tests . 
In this study, low MICs of ECO, ITC, TRB and GSF have been reported. However, FLC had the 
highest MIC value against all the clinical dermatophyte strains 
36,37
. TRB was the most effective 
antifungal against T.rubrum and T.interdigitale species causing onychomycosis and tinea pedis. 
Previous studies 
38-41
 reported that TRB has a higher clinical cure with a slower relapse rates in a 
short period of treatment 
42
. GSF was the first systemic treatment for skin and nail infections but 
demonstrate a limited spectrum activity to dermatophytes
43,44
. Moreover, GSF demonstrate a 
MIC values >16 µg ml
-1
 against some resistant dermatophyte isolates 
44,45
 In addition, we note 
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that GSF is less active against T.rubrum and T. interdigitale than the other antifungal agents 
beyond FLC. 
Concerning the derivative azoles, ITC and ECO were demonstrated to be the most active agents 
against Trichophyton spp. agents of tinea pedis and tinea unguium
46,47
; otherwise, ITC was more 
effective in tinea pedis than ECO this finding is confirmed by study of Decroix. 1995 
48
 showing 
a successful oral treatment of tinea pedis with ITC. However FLC showed a high MIC values 
(>64µg ml
-1
) especially for species related to tinea pedis. These differences in the susceptibility 
can be explained by the fact that derivate azoles target fungal ergosterol in the structure differs 
among species. 
In the present study, also NDMs such as Fusarium spp, S. brevicaulis, and A. terreus and C. 
keratinophylum were isolated from patients with foot mycosis. The treatment of tinea pedis and 
tinea unguium caused by NDMs is still not well standardized and many authors point out the poor 
therapeutic response of these fungal infections to systemic antifungal drugs 
49-52
. We found that 
azoles (FLC, ECO, and ITC) and GSF showed a very high MICs values for the strains of S. 
brevicaulis and Fusarium spp. However, TRB presents a low MICs values for the strains of S. 
brevicaulis and F. oxysporum. In the other hand, the isolates of F. solani are resistant to all the 
antifungal tested, this can be explained by the characteristics of Fusarium species to be refractory 
and represents in vivo and in vitro resistance to most antifungal drugs 
53-56
. 
The capacity of dermatophyte and NDM isolates to form biofilms is generally related to the 
ability to cause infection. In the present work, we have assessed the biofilm production by 
dermatophytes and NDMs associated to foot mycosis. Otherwise, a first work has reported the in 
vitro biofilm forming abilities of T. rubrum and T. mentagrophytes 
19
, and many other studies 
reported the biofilm formation of some filamentous fungi 
25,57
 . However, to our knowledge, the 
biofilm production by molds S. brevicaulis and C. keratinophylum associated to foot mycosis has 
not been described. Overall, all the isolates had the ability to adhere to the polystyrene surface 
and form biofilm in different degrees depending on the species. In the present study, the species 
of F. solani (M7, M8) and S. brevicaulis (M3, M6) resistant clinical isolates, showed the most 
capacity to form biofilm on a polystyrene surface. These finding let us suppose that the high 
production of biofilm, that is a permeability barrier surprisingly resistant to injury, could 
contribute to their survival, act as a persistent source of infection and further dissemination and 
account for antifungal resistance in onychomycosis 
58,59
 . The low susceptibility of Fusarium 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
biofilm (M2 and M8) to the tested antifungal agents, could confirmed the hypothesis of Seidler et 
al.  
25
.  
The maturation of biofilm and the high cell density in the biofilm matrix may influence the 
different susceptibility to antifungal drugs. 
Many factors suggest that biofilm represent an important role in the pathogenesis of 
onychomycosis including firm adherence of dermatophytes in the nail plate and ability to form 
biofilm, which increased of virulence and resistance to the antimicrobial agents (Nusbaum et al., 
2012).  
The differences in anti-biofilm assays, among dermatophyte and NDM species, can be related to 
the life cycle of biofilm especially in the maturation stage associated to the composition of the 
biofilm matrix and the rate of the drug diffusion through the biofilm. 
Successful treatment of onychomycosis can be explained in first by the biofilm formation and for 
the susceptibility assay, antifungal agents should be tested among biofilms and not planktonic 
cells. Biofilm assays performed in vitro could allow for rapid screening of antifungal compounds. 
Appropriate selection of antifungal agents with adequate dose could help to resolve the infection 
and reduce its spread. In the recommendations given by ESCMID there is the urgent need to 
standardized biofilm susceptibility test and to biofilm-specific breakpoints for systemic and 
topically administered antibiotics 
60
. 
Therefore, the increased levels of biofilm resistance underline the importance of developing 
assays to test biofilm antifungal susceptibilities. Such future research in antifungal drugs and 
their exact mode of action against dermatophyte and NDM biofilms are needed to be developed 
in order to target sessile cells. 
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Figure legends 
Figure 1. Quantification of biofilm biomass formation after 72h is represented by crystal violet 
absorbance at 570 nm (A) and safranin absorbance at 492 nm (B). Error bars represent standard 
deviation 
Figure 2. Inhibition percentage of biofilm formation of dermatophyte and non-dermatophyte 
strains using different concentrations of econazole and terbinafine. Data are percentage of the 
mean of triplicates with respect to control. Error bars represent standard deviation. 
 
 
Table1. Identification of dermatophyte and non-dermatophyte clinical strains used in this study 
Strains Sex Clinical diagnosis Clinical aspect Identification 
(MALDI-TOF MS) 
T4 F Tinea pedis PD T.rubrum 
T5 M Onychomycosis DLSO T.rubrum 
T7 M Onychomycosis DLSO T.rubrum 
T9 M Onychomycosis PSO T.rubrum 
T11 M Onychomycosis DLSO T.rubrum 
T12 F Onychomycosis TDO T.rubrum 
T13 F Onychomycosis DLSO T.rubrum 
T18 F Onychomycosis DLSO T.rubrum 
T21 F Onychomycosis DLSO T.rubrum 
T22 p M Tinea pedis PH T.rubrum 
T23 F Onychomycosis TDO T.rubrum 
T25 F Onychomycosis DLSO T.rubrum 
T39 M Onychomycosis TDO T.rubrum 
T40 M Tinea pedis PH T.rubrum 
T42 M Onychomycosis PSO T.rubrum 
T46 F Onychomycosis DLSO T.rubrum 
T52 M Onychomycosis TDO T.rubrum 
T56 M Onychomycosis DLSO T.rubrum 
T61 F Tinea pedis ID T.rubrum 
T64 M Onychomycosis PSO T.rubrum 
T66 F Onychomycosis DLSO T.rubrum 
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T103 M Onychomycosis DLSO T.rubrum 
T1 F Onychomycosis DLSO T.rubrum 
T34I F Tinea pedis ID T.interdigitale 
T44 M Onychomycosis DLSO T.interdigitale 
T45 F Onychomycosis TDO T.interdigitale 
T68 F Onychomycosis TDO T.interdigitale 
M1 F Onychomycosis TDO F. oxysporum 
M2 F Onychomycosis DLSO F. oxysporum 
M3 M Onychomycosis DLSO S. brevicaulis 
M6 F Onychomycosis DLSO S. brevicaulis 
M12 F Onychomycosis DLSO S.brevicaulis 
M5 F Onychomycosis DLSO A. terreus 
M7 F Onychomycosis DLSO F. solani 
M8 F Onychomycosis DLSO F. solani 
T37 F Onychomycosis DLSO C. keratinophylum 
M13 M Onychomycosis DLSO C. keratinophylum 
NDMs:  DLSO: Distal lateral subungual onychomycosis; ID: Interdigital; PD: Plantar 
dishydrosis; PH: Plantar hyperkeratosis; PSO: Proximal subungual  onychomycosis; TDO: Total 
dystrophic onychomycosis. A: Aspergillus; C: Chrysosporium; F: Fusarium; S: Scopulariopsis; 
T: Trichophyton.  
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Antifungal agents FLC MIC(µg ml
-1
) ECO MIC(µg ml
-1
) ITC MIC(µg ml
-1
) TRB MIC(µg ml
-1
) GSF MIC(µg ml
-1
) 
Strains MIC50 MIC80 MIC100 MIC50 MIC80 MIC100 MIC50 MIC80 MIC100 MIC50 MIC80 MIC100 MIC50 MIC80 MIC100 
Dermatophytes 
(n=26) 
               
Trichophyton 
rubrum (n=21) 
               
T4 32 64 >64 <0.125 <0.125 <0.125 ND 0.25 0.5 <0.031 <0.031 <0.031 0.5 1 ND 
T5 4 16 64 <0.125 <0.125 <0.125 <0.031 <0.031 <0.031 <0.031 <0.031 <0.031 0.5 2 4 
T7 16 16 >64 <0.125 <0.125 <0.125 <0.031 <0.031 <0.031 <0.031 <0.031 <0.031 0.5 1 ND 
T9 32 64 >64 <0.125 <0.125 <0.125 <0.031 <0.031 <0.031 <0.031 <0.031 <0.031 4 8 >16 
T11 1 1 16 <0.125 <0.125 <0.125 0.062 0.062 0.5 <0.031 <0.031 <0.031 >16 >16 >16 
T12 0.125 0.125 4 <0.125 <0.125 <0.125 <0.031 <0.031 <0.031 <0.031 <0.031 <0.031 0.5 1 2 
T13 8 16 32 <0.125 <0.125 <0.125 <0.031 <0.031 <0.031 <0.031 <0.031 <0.031 1 1 2 
T18 32 32 64 <0.125 <0.125 <0.125 0.125 0.25 0.5 <0.031 <0.031 <0.031 1 2 4 
T21 64 64 >64 <0.125 <0.125 <0.125 16 16 >16 <0.031 <0.031 <0.031 0.5 1 2 
T22P 8 16 64 <0.125 <0.125 <0.125 0.125 0.125 0.25 <0.031 <0.031 <0.031 0.5 1 2 
T23 0.5 1 2 <0.125 <0.125 <0.125 0.031 0.062 0.062 <0.031 <0.031 <0.031 1 2 4 
T25 4 4 8 <0.125 <0.125 <0.125 0.125 0.25 0.5 <0.031 <0.031 <0.031 4 8 16 
T39 4 8 32 <0.125 <0.125 <0.125 0.125 0.25 0.5 <0.031 <0.031 <0.031 ND ND ND 
T40 16 64 >64 32 64 >64 0.25 0.25 0.5 <0.031 <0.031 <0.031 0.5 1 2 
Table 2. Minimum inhibitory concentration (MIC) of five antifungal agents against dermatophyte and non-dermatophyte clinical strains 
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T42 8 32 >64 16 32 64 0.125 0.25 0.5 <0.031 <0.031 <0.031 0.5 1 >16 
T46 16 16 >64 <0.125 <0.125 <0.125 <0.031 <0.031 <0.031 <0.031 <0.031 <0.031 0.5 1 ND 
T52 >64 >64 >64 <0.125 <0.125 <0.125 0.125 0.125 0.5 <0.031 <0.031 <0.031 ND ND ND 
T56 2 2 64 <0.125 <0.125 <0.125 0.065 0.065 0.065 <0.031 <0.031 <0.031 ND ND ND 
T61 >64 >64 >64 <0.125 <0.125 <0.125 0.062 0.125 0.25 <0.031 <0.031 <0.031 1 2 4 
T64 4 8 64 <0.125 <0.125 <0.125 0.062 0.25 0.5 <0.031 <0.031 <0.031 ND ND ND 
T66 0.125 0.125 >64 <0.125 <0.125 <0.125 <0.031 <0.031 <0.031 <0.031 <0.031 <0.031 1 2 4 
T103 0.5 2 64 <0.125 <0.125 <0.125 0.062 0.125 0.5 <0.031 <0.031 <0.031 ND ND ND 
 
 
Trichophyton 
interdigitale (n=5) 
               
T1 64 64 >64 <0.125 <0.125 <0.125 <0.031 <0.031 <0.031 <0.031 <0.031 <0.031 0.5 1 2 
T34I 64 >64 >64 <0.125 <0.125 <0.125 0.125 0.25 0.25 <0.031 <0.031 <0.031 0.5 1 2 
T44 0.5 0.5 1 <0.125 <0.125 <0.125 <0.031 <0.031 <0.031 <0.031 <0.031 <0.031 0.5 1 >16 
T45 64 64 >64 <0.125 <0.125 <0.125 0.065 0.065 0.125 <0.031 <0.031 <0.031 1 2 4 
T68 >64 >64 >64 <0.125 <0.125 <0.125 0.125 0.25 0.5 <0.031 <0.031 <0.031 1 2 4 
Molds (n=10)                
Fusarium 
oxysporum (n=2) 
               
M1 >64 >64 >64 1 2 4 32 >16 >16 1 2 4 >16 >16 >16 
M2 >64 >64 >64 4 8 16 >16 >16 >16 4 8 16 >16 >16 >16 
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Fusarium solani 
(n=2) 
               
M7 >64 >64 >64 >64 >64 >64 >16 >16 >16 >16 >16 >16 >16 >16 >16 
M8 >64 >64 >64 64 >64 >64 >16 >16 >16 >16 >16 >16 ND ND ND 
Scopulariopsis 
brevicaulis (n=3) 
               
M3 >64 >64 >64 16 >64 >64 >16 >16 >16 4 8 16 >16 >16 >16 
M6 >64 >64 >64 8 16 >64 >16 >16 >16 1 2 8 >16 >16 >16 
M12 >64 >64 >64 0.5 1 4 >16 >16 >16 0.25 0.25 2 >16 >16 >16 
Aspergillus terreus                 
M5 >64 >64 >64 <0.125 <0.125 <0.125 <0.031 <0.031 <0.031 <0.031 <0.031 <0.031 >16 >16 >16 
Chrysosporium 
keratinophylum 
(n=2) 
               
T37 8 8 16 <0.125 <0.125 <0.125 <0.031 <0.031 <0.031 <0.031 <0.031 <0.031 2 4 8 
M13 2 4 8 <0.125 <0.125 <0.125 <0.031 <0.031 <0.031 <0.031 <0.031 <0.031 0.25 0.5 1 
T. mentagrophytes 
DSM 4870 
64 64 >64 <0.031 <0.031 <0.031 >64 >64 >64 <0.031 <0.031 <0.031 1 2 4 
A. terreus DSM 
1958 
>64 >64 >64 <0.031 <0.031 <0.031 0.065 0.065 0.065 <0.031 <0.031 <0.031 >16 >16 >16 
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FLC: fluconazole; ECO: econazole; ITC: itraconazole; TRB: terbinafine; GSF: griseofulvin; MIC50 : the lowest concentration that 
caused ≥ 50% growth inhibition; MIC80 : the lowest concentration that caused 80% growth inhibition; MIC100 :the lowest drug 
concentration that inhibited 100% of growth. 
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